Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KPI-121 0.25% in Inflammatory Meibomian Gland Disease
NCT02218489Phase 2Completed
- Sponsor
- KALA BIO
- Start
- Jul 2014
- Primary completion
- Dec 2015
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of loteprednol etabonate ophthalmic gel 0.38% in Meibomian gland dysfunction (MGD) and blepharitis (2 arms), sponsored by KALA BIO. Primary endpoints: Change From Baseline in Ocular Discomfort at Day 15 and Change From Baseline in Posterior Lid Margin Hyperemia in the Subgroup of Subjects With Greater Hyperemia at Baseline at Day 15. Started Jul 2014; status: completed.
02
Drugs
loteprednol etabonate ophthalmic gel 0.38%
03
Conditions
Meibomian gland dysfunction (MGD)blepharitis
Beyond the preview
Go deeper on NCT02218489.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02218489.